Double Blind Randomized Phase III Study of Maintenance Pazopanib® (Pz) Versus Placebo (P) in Non Small Cell Lung Cancer (Nsclc) Patients (Pts) Non Progressive After First Line Chemotherapy [Ct] (Eortc Lung Cancer Group, 08092): Mapping

Aim: Switch maintenance is an effective strategy in advanced NSCLC treatment. Pz is an orally active, multi-targeted tyrosine kinase inhibitor (TKI), potentially effective in lung cancer. EORTC 08092 evaluated Pz given as maintenance following standard first line platinum-based chemotherapy (CT) in pts with advanced NSCLC.